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We describe a human immunodeficiency virus–positive
woman who presented with severe psychosis while she was
receiving therapy with efavirenz. Her plasma efavirenz level
was excessively high. Genetic investigation showed that she
was homozygous for the CYP2B6 G516T allele, resulting in
slow hepatic metabolism. After the dosage of efavirenz was
lowered, all neuropsychiatric symptoms subsided.
In the care of HIV-infected patients receiving antiretroviral
therapy (ART), clinicians are often confronted with drug tox-
icities and adverse effects. Most of these toxicities develop de-
spite correct dosing. In cases in which there is significant tox-
icity, drug treatments are usually withdrawn regardless of the
drug serum level. We report the case of a patient who presented
at our hospital (Cantonal Hospital of Muensterlingen, Muen-
sterlingen, Switzerland) with sudden and severe neuropsychi-
atric symptoms during therapy with efavirenz (EFV). To our
knowledge, the patient presented with the highest plasma level
of EFV ever reported in the literature.
Case report. A 33-year-old, HIV-infected woman who was
a native of Thailand was referred to our hospital because of
symptoms of acute psychosis. There was no history of previous
mental illness. Her husband stated that there had been a 2-
week history of confusion, childish behaviour, and verbal ag-
gressiveness. She had stopped taking her antiretroviral agents
5 days before presentation. She stated that, after the cessation
of her therapy, she already felt better.
She was known to have been HIV positive since 1994, and
her nadir CD4 cell count was cells/L. She had been68 10
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treated for cryptococcal meningitis in the past and had already
received regimens of several combinations of antiretroviral
agents. According to the results of a drug resistance test, she
had started a treatment regimen 1 month before admission to
the hospital that consisted of lopinavir-ritonavir (400/100 mg
twice daily), tenofovir (300 mg once daily), and EFV (600 mg
once daily). She was concomitantly receiving fluconazole (400
mg once daily) and trimethoprim-sulfamethoxazole (160/800
mg 3 times per week).
Findings of a complete physical examination and laboratory
tests, a lumbar puncture, and MRI of the brain were normal.
The CD4 cell count was cells/L, and the viral load was686 10
36 copies/mL. Almost 1 week after the discontinuation of treat-
ment, all psychiatric symptoms had resolved. Because an in-
teraction between EFV and fluconazole was suspected, the dos-
age of the antifungal agent was reduced from 400 mg to 200
mg once daily, and the same ART regimen was restarted.
One week later, psychiatric symptoms reappeared. Again,
the patient was confused and aggressive, but, this time, she
also experienced symptoms of severe depression. Because she
wanted to commit suicide with a butcher’s knife, she was ur-
gently admitted to a psychiatric ward. Her plasma EFV level
was 59.4 mg/L, which is ∼30-fold more than the normal limit.
One week after ART was discontinued, the patient recovered
completely and was discharged from the hospital. The plasma
EFV level declined slowly (see figure 1). Subsequently, ART was
restarted with a reduced dose of EFV (200 mg once daily). No
psychiatric symptoms reappeared. While the patient was re-
ceiving EFV at dosages of 200 mg once daily, the plasma drug
levels were normal (i.e., in the 50th percentile). After month
6 of therapy, the CD4 cell count was cells/L, and the6120 10
viral load was suppressed. Genetic investigation showed that
the patient was homozygous for the CYP2B6 G516T allele.
Discussion. Of patients treated with EFV, 54% develop
CNS adverse effects [1–3]. The most common adverse effects
are confusion, insomnia, vivid dreams, dizziness, and head-
aches. These symptoms usually begin shortly after the first days
of therapy and generally resolve after 2–4 weeks of therapy.
Serious psychiatric effects, including depression, hallucinations,
aggression, mania, and psychosis, have been reported less com-
monly [4–6]. The risk of serious CNS adverse effects associated
with use of EFV is greater in patients with mental illness or
substance abuse disorders [7]. In patients without such risk
factors, high plasma EFV levels are responsible for serious psy-
chiatric complications [8, 9], but the clear relationship between
the plasma concentrations, the pharmacokinetics, and the clin-
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Figure 1. All plasma efavirenz levels were measured 14 h after the
last ingestion of the medication. The normal level (i.e., in the 50th per-
centile) at that time point is 2 mg/L (dashed line).
ical CNS adverse effects of EVF is still being investigated. EFV
is metabolized primarily by the hepatic cytochrome CYP2B6,
a hepatic mixed-function oxidase [10]. Interindividual func-
tional differences in CYP2B6 activity are responsible for dif-
ferent susceptibility to EFV-associated CNS adverse effects [11,
12]. The CYP2B6 G516T mutation is associated with signifi-
cantly reduced function of the 2B6 enzyme [13]. Because the
patient we describe was homozygous for this mutation, we
postulate that slow hepatic metabolism was primarily respon-
sible for the excessively high plasma EFV levels. Furthermore,
a drug interaction with fluconazole might have contributed to
the accumulation of EFV, because fluconazole has been shown
to prolong the elimination half-life of EFV. However, under
normal circumstances, no dose adjustment is recommended
when EFV and fluconazole are given concomitantly. CYP2B6
G516T mutations are relatively common among black and His-
panic persons [14], but the prevalence of the mutations among
Asian persons is not known at this time, and the mutation may
be common.
In conclusion, for persons who develop neuropsychiatric side
effects while receiving treatment with EFV, we recommend
keeping EFV in the therapeutic armentarium and lowering the
dosage, rather than simply stopping treatment with the drug.
Additional studies should be performed to evaluate whether
genetic investigations should be undertaken before initiation
of EFV treatment.
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